According to a Glaxo-funded clinical trial, Glaxo’s Cervarix vaccine induced a higher immune response in women against the human papilloma virus (HPV) than Merck"s Gardasil. At the moment, the FDA is reviewing Cervarix and will decide whether to approve it by autumn. Glaxo hopes the trial results will help give Cervarix a competitive advantage.